precisionmedicineonline21h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Maze Therapeutics begins Phase 2 trial for kidney disease drug
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...
Health Affairs23h
Addressing The Harmfully Slow Uptake Of Race-Neutral Kidney Function Tests
A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...
Maze Therapeutics doses first patient in Phase 2 HORIZON trial
Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...
Hosted on MSN1d
Ozempic Now FDA-Approved for Kidney Disease-Here's What to Know
GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
Healio2d
Older adults with kidney disease face psychosocial barriers in transplant evaluation
Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...
Rolling Out5d
12 signs of kidney disease Black people shouldn’t ignore
Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...